Abstract: A fusion protein has the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. A composition having the fusion protein may improve skin wrinkle with increased anti-oxidant activity and skin cell proliferation effect. It can be advantageously used as a raw material of a functional cosmetic having an excellent skin regeneration effect like improvement of skin wrinkles and skin whitening.

Abstract: A botulinum toxin-human epidermal growth factor fusion protein with increased skin cell proliferation and anti-oxidation effect has the amino acid sequence of SEQ ID NO: 2, a gene consisting of E. coli (Escherichia coli) codon-optimized nucleotide sequence of SEQ ID NO: 1 for encoding the botulinum toxin-human epidermal growth factor fusion protein, a recombinant vector including the gene, a host cell transformed with the recombinant vector, and a method for producing a botulinum toxin-human epidermal growth factor fusion protein by transforming a host cell with the recombinant vector, and a cosmetic composition for regenerating skin and improving skin wrinkle including, as an effective component, a botulinum toxin-human epidermal growth factor fusion protein, and as the cosmetic composition has an effect of regenerating skin and improving skin wrinkle, it can be advantageously used in future in the field of cosmetics or cosmetic plastic surgery.

Abstract: A botulinum toxin-human epidermal growth factor fusion protein with increased skin cell proliferation and anti-oxidation effect has the amino acid sequence of SEQ ID NO: 2, a gene consisting of E. coli (Escherichia coli) codon-optimized nucleotide sequence of SEQ ID NO: 1 for encoding the botulinum toxin-human epidermal growth factor fusion protein, a recombinant vector including the gene, a host cell transformed with the recombinant vector, and a method for producing a botulinum toxin-human epidermal growth factor fusion protein by transforming a host cell with the recombinant vector, and a cosmetic composition for regenerating skin and improving skin wrinkle including, as an effective component, a botulinum toxin-human epidermal growth factor fusion protein, and as the cosmetic composition has an effect of regenerating skin and improving skin wrinkle, it can be advantageously used in future in the field of cosmetics or cosmetic plastic surgery.

Abstract: A method for treating wrinkle or aging on a skin of a subject includes applying to the skin a composition that includes a green fluorescent protein-human epidermal growth factor fusion protein as an effective component. Since the fusion protein has an excellent anti-oxidation activity and a high skin cell proliferation effect, it can be advantageously used as a raw material of functional cosmetics having excellent skin regeneration effect like improvement of skin wrinkles and skin whitening.

Abstract: A thermostable human epidermal growth factor-spider venom fusion protein with increased skin cell proliferation effect has the amino acid sequence of SEQ ID NO: 2, a gene of E. coli codon-optimized nucleotide sequence of SEQ ID NO: 1 for encoding the human epidermal growth factor-spider venom fusion protein, a recombinant vector including the gene, a host cell transformed with the recombinant vector, and a method for producing in a host cell a human epidermal growth factor-spider venom fusion protein by transforming a host cell with the recombinant vector, and a cosmetic composition for improving skin wrinkle and maintaining skin elasticity including a human epidermal growth factor-spider venom fusion protein, and as the cosmetic composition has excellent thermostability and has an effect of enhancing the activity of improving skin wrinkle and maintaining skin elasticity, it can be advantageously used in future in the field of cosmetics or cosmetic plastic surgery.

Abstract: A thermostable human epidermal growth factor-spider venom fusion protein with increased skin cell proliferation effect has the amino acid sequence of SEQ ID NO: 2, a gene of E. coli codon-optimized nucleotide sequence of SEQ ID NO: 1 for encoding the human epidermal growth factor-spider venom fusion protein, a recombinant vector including the gene, a host cell transformed with the recombinant vector, and a method for producing in a host cell a human epidermal growth factor-spider venom fusion protein by transforming a host cell with the recombinant vector, and a cosmetic composition for improving skin wrinkle and maintaining skin elasticity including a human epidermal growth factor-spider venom fusion protein, and as the cosmetic composition has excellent thermostability and has an effect of enhancing the activity of improving skin wrinkle and maintaining skin elasticity, it can be advantageously used in future in the field of cosmetics or cosmetic plastic surgery.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: A spider venom (SV) 82 polypeptide has an amino acid sequence of SEQ ID NO: 2. An SV82 polypeptide-encoding gene having a nucleotide sequence of SEQ ID NO: 1 which is optimized for E. coli codon. A recombinant vector includes the SV82 polypeptide-encoding gene, An E. coli is transformed with the recombinant vector. A method of producing SV82 polypeptide includes transforming a host cell with the recombinant vector. A cosmetic composition for reducing skin wrinkles and maintaining skin elasticity includes SV82 polypeptide as an active ingredient.

Abstract: A spider venom (SV) 82 polypeptide has an amino acid sequence of SEQ ID NO: 2. An SV82 polypeptide-encoding gene having a nucleotide sequence of SEQ ID NO: 1 which is optimized for E. coli codon. A recombinant vector includes the SV82 polypeptide-encoding gene, An E. coli is transformed with the recombinant vector. A method of producing SV82 polypeptide includes transforming a host cell with the recombinant vector. A cosmetic composition for reducing skin wrinkles and maintaining skin elasticity includes SV82 polypeptide as an active ingredient.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.

Abstract: A web control system for solar tracking includes one or more trackers, a communication port management unit, a status processing unit, a tracker control unit, a back tracking unit, a web server unit, and the memory unit. The trackers operate in compliance with driving commands and change the position of a solar cell panel in response to the tracking of the location of a sun. The communication port management unit is responsible for data transmission and reception. The status processing unit scans the status of the trackers. The tracker control unit directly controls the trackers. The back tracking unit analyzes the status information, and controls the tracker control unit. The local GUI interface unit displays a local or remote user screen. The web server unit provides the GUI data to a user. The memory unit stores the information.